For example, there was a higher risk of cancer in patients who took tofacitinib than an anti-tumor necrosis factor (TNF) agent after 18 months of therapy for rheumatoid arthritis, according to a post-hoc analysis [17] of a randomized controlled trial (ORAL SURVEILLANCE) [15]. This evidence concerns the gene TNF and rheumatoid arthritis.